Risk-Benefit Analysis of CAR-T Therapies for Myeloma is Muddy by Early Death Risk.

Published Date: 18 Mar 2024

In a full day of meetings, the FDA advisory panel will assess the evidence for cilta-cel and ide-cel.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

3D virtual staining technology enables non-invasive observation of cancer tissue

2.

Risk-Benefit Analysis of CAR-T Therapies for Myeloma is Muddy by Early Death Risk.

3.

BMI is linked to heart damage from chemotherapy in breast cancer patients.

4.

New Gene Therapy Nears EU Nod for Bladder Cancer

5.

Advanced Solid Tumors May Benefit from Investigative Immunotherapy Combo.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot